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Abstract
Background: Tendon disease is characterized by the development of fibrosis. Transforming growth factor beta
(TGF-β), bone morphogenic proteins (BMPs) and connective tissue growth factor (CTGF) are key mediators in the
pathogenesis of fibrotic disorders. The aim of this systematic review was to investigate the evidence for the
expression of TGF-β, BMPs and CTGF along tendon disease progression and the response of tendon cells to these
growth factors accordingly.
Method: We conducted a systematic screen of the scientific literature using the Medline database. The search
terms used were “tendon AND TGF-β,” “tendon AND BMP” or “tendon AND CTGF.” Studies of human samples,
animal tendon injury and overuse models were included.
Results: Thirty-three studies were included. In eight studies the expression of TGF-β, BMPs or CTGF was
dysregulated in chronic tendinopathy and tendon tear patient tissues in comparison with healthy control tissues.
The expression of TGF-β, BMPs and CTGF was increased and showed temporal changes in expression in tendon
tissues from animal injury or overuse models compared with the healthy control (23 studies), but the pattern of
upregulation was inconsistent between growth factors and also the type of animal model. No study investigated
the differences in the effect of TGF-β, BMPs or CTGF treatment between patient-derived cells from healthy and
diseased tendon tissues. Tendon cells derived from animal models of tendon injury showed increased expression of
extracellular matrix protein genes and increased cell signaling response to TGF-β and BMP treatments compared
with the control cells (two studies).
Conclusion: The expression of TGF-β, BMPs and CTGF in tendon tissues is altered temporally during healing in
animal models of tendon injury or overuse, but the transition during the development of human tendon disease is
currently unknown. Findings from this systematic review suggest a potential and compelling role for TGF-β, BMPs
and CTGF in tendon disease; however, there is a paucity of studies analyzing their expression and stimulated
cellular response in well-phenotyped human samples. Future work should investigate the dynamic expression of
these fibrotic growth factors and their interaction with tendon cells using patient samples at different stages of
human tendon disease.
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Background
Tendon diseases are increasingly common fibrotic disor-
ders [1, 2] and account for a third of all musculoskeletal
complaints [3]. The patella, Achilles and rotator cuff
(RC) tendons are the most frequently affected sites [4].
Tendon disorders are generally described by the term
“tendinopathy” that includes diseases of the tendon and
also tendon–bone junctions, namely enthesopathy or
enthesitis [5]. The development of tendon disease has
been proposed to start from an acute reactive tendinopa-
thy, and subsequent dysregulated healing or disrepair
may cause progression to chronic tendinopathy [6, 7].
The etiology is multifactorial, with overuse, trauma,
aging and genetic predisposition regarded as notable risk
factors [8, 9]. Recent studies have indicated the key role
of inflammation in the homeostasis and healing of ten-
don, and its dysregulation may therefore contribute to
the accumulation of mechanically inferior fibrotic ten-
don tissue [10, 11]. This results in an inappropriate func-
tion of the tendon, higher risk of reinjury [12] and
tendon rupture [6]. Torn tendons are usually treated by
surgical repair, but the postoperative retear rate remains
high at around 40 % in operated RC tears [13]. A clinical
need therefore exists for improved understanding of the
mechanisms underlying both tendon disease and suc-
cessful repair.
Studies of fibrotic diseases in other organs such as the
liver, lung and kidney have implicated the members of the
transforming growth factor beta (TGF-β) superfamily as
key fibrotic growth factors [14] and proposed them as ef-
fective biomarkers for fibrotic changes [15]. TGF-β and
bone morphogenic proteins (BMPs) are the two major
members of the superfamily, the former known as a key
regulator of fibrosis and repair. BMPs also contribute to fi-
brosis by guiding cell differentiation and the subsequent
synthesis of extracellular matrix (ECM) proteins. TGF-β
and BMPs both utilize the canonical Smad cell-signaling
pathway, which also has been suggested to have crosstalk
between the two [16]. Connective tissue growth factor
(CTGF) belongs to the CCN family (CTGF, cysteine rich
protein (Cyr61) and nephroblastoma overexpressed gene
(Nov)) but is one of the key profibrotic mediators and acts
closely with TGF-β as its downstream mediator. The ex-
pression of these growth factors has been reported to
change over the progression of fibrotic liver diseases from
hepatitis, cirrhosis to carcinogenesis [17, 18], and the cel-
lular response to these fibrotic mediators differs accord-
ingly [19].
The aim of this study was to investigate the role of
TGF-β, BMPs and CTGF in the pathophysiology of ten-
don disease via a systematic review. The first objective
was to investigate the gene and protein expression of
TGF-β, BMPs and CTGF in diseased tendons along the
development of disease from tendinopathy to tear in
comparison with the healthy tendon tissues. The second
objective was to investigate whether cellular response to
treatment with TGF-β, BMPs or CTGF was dysregulated
in tendon cells from diseased tendons. Animal studies of
tendon injury and overuse models were also reviewed.
We hypothesized that the expression of TGF-β, BMPs
and CTGF in diseased or injured tendon tissues and the
cellular responses to these growth factors would change
between normal tendon, early and late disease or heal-
ing. Understanding disease progression in relation to the
expression and cellular activity of these key fibrotic
mediators should help identify their potential role in the
pathogenesis of tendon disease.
Methods
Search strategies
This systematic review was designed, undertaken and re-
ported based on the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA)
Statement and the Cochrane guidelines. The inclusion
criteria and analysis methods were defined and stated in
a protocol prior to the study. Scientific literature was ob-
tained using the Medline electronic database. The search
was conducted in September 2016 with the following
search terms: “tendon AND TGF-β,” “tendon AND
BMP” and “tendon AND CTGF.” The reports retrieved
by the searches were compiled and duplicates were re-
moved. The abstract of the papers was screened before
the assessment for eligibility by reviewing the full text of
the articles.
The studies reporting the expression of the growth
factors in diseased human tendon tissues, animal models
of tendon injury or overuse had to relate to the mid-
substance of tendon or tendon-to-bone enthesis, and
therefore studies on muscle–tendon junctions, ligament
reconstruction using tendon grafts and other soft tissues
(e.g. muscles, ligaments, bursa and synovial tissues) were
excluded. The included studies had to involve a control
group. The animal studies of injury healing had to follow
and report the temporal course of repair in comparison
with the control. Animal overuse models were included
when the development of tendinopathy was verified
based on histological findings such as infiltration of in-
flammatory cells, changes in cellularity/cell phenotype,
vascularity and disorganized or ruptured collagen fibers
[5, 20]. The in vitro studies had to relate cell phenotype
depending on the presence of disease to the cellular ac-
tivity in response to treatment by TGF-β, BMPs or
CTGF. Review articles, case reports and studies that
were not reported in English were excluded. There was
no limitation in the year of data entry, although all of
the results were published after 1985.
The data extracted were summarized using a spreadsheet
that included patient or animal model characteristics,
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method of tissue or cell analysis, the control group, results
and statistical methods.
Study selection
The search yielded 592 results (Fig. 1). There were 532
papers after duplicates were removed, and 442 papers
remained after review articles, case reports and articles
that were not in English were removed. Screening of the
paper abstracts based on the criteria set beforehand re-
duced this number to 43. Assessment for eligibility
through the full text resulted in 33 papers meeting the
criteria. The reasons for excluding the remaining 10 pa-
pers were no control group (n = 3), no temporal com-
parison of the expression of the growth factors in animal
studies (n = 4) and no verification of the development of
tendinopathy in an animal overuse model (n = 3). The
papers that met the inclusion criteria are summarized in
Tables 1, 2 and 3.
Study characteristics
Only one study compared the expression of TGF-β,
BMPs and CTGF between different stages of human ten-
don disease in the RC. Seven studies compared the dif-
ferences in the expression of at least one of the growth
factors between tendinopathic and healthy tendon
tissues in the patella, Achilles or RC (Table 1). However,
the tissue was sampled from calcific tendinopathy
patients in one study and another study compared the
expression of the proteins after an intervention by exer-
cise. Sixteen, seven and eight studies respectively
reported the temporal expression of TGF-β, BMPs and
CTGF in animal models of tendon injury or overuse
(Table 2). The injury models varied by using the patella,
Achilles, RC or flexor digitorum (FD) tendons in mice,
rats, chickens, rabbits or horses, with injuries or defects
created by transection, crush injury, use of collagenase
or longitudinal division. Whether the transected tendons
were repaired surgically or spontaneous healing was
observed depended on the study. The development of
tendinopathy was verified by histology in the overuse
models, which used the RC or FD tendons in rats or rab-
bits. No study compared the differences in the cellular
response to TGF-β, BMPs or CTGF in healthy and dis-
eased cells from human tendons. One study used rat
tendon cells from the patella of a collagenase-induced
(CI) tendon injury model and another from a rat patella
defect model, and treated the cells in vitro with BMP2
and TGF-β, respectively (Table 3). The cellular response
to these growth factors was measured by the cell prolif-
eration rate, expression of ECM-related genes and phos-
phorylation level of the Smad proteins, which are the
key mediators of the TGF-β and BMP cell-signaling
pathway.
Study methodology and assessing the risk of bias
The quality of study methodology was assessed by refer-
ring to the modified scoring system by Dean et al. [21]
in order to highlight the studies with a high risk of
potential bias (Additional file 1). The mean (standard de-
viation) score was 7.73 (1.28) out of 10. All included
studies had a control group, although in two studies the
“control” samples were obtained from a macroscopically
healthy area of the same tendon that may be at a risk of
bias. Ten animal studies did not clarify the age or sex of
the animals used. The methods of tissue and cell sam-
pling and analysis were clearly described in all studies.
Seven studies did not use quantitative measures or stat-
istical analysis for comparison. The data were checked
for normality in only four studies. All except 11 studies
stated the set statistical significance. Two studies set p <
0.01 with consideration for an increased type I error by
performing multiple tests, but the remaining studies set
p < 0.05. The limitations of the study were not addressed
Fig. 1 Flow chart of the systematic review protocol
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in 13 studies. Meta-analysis was not performed due to
the heterogeneity of the identified studies.
Results
Expression of TGF-β, BMPs and CTGF in diseased human
tendon tissues
The expression of TGF-β, BMPs and CTGF was dysreg-
ulated at different stages of tendon disease (Table 4); the
single study that compared the protein expression of
these growth factors between torn, tendinopathic and
healthy RC tissues reported a decreased expression of
TGF-β and its receptors in the diseased tendon tissues
of both chronic tendinopathy and tear [22]. Gene and
protein expression of TGF-β and protein expression of
BMP2, BMP4 and BMP7 were increased in the six stud-
ies that compared tendinopathy and healthy tendon tis-
sues from the patella or the Achilles [23–28]. The gene
expression of BMP4 and BMP6 was suppressed in the
calcific area of calcific tendinopathy of the RC [29]. The
diagnosis of chronic tendinopathy was made clinically in
all seven studies of human disease, with auxiliary im-
aging methods such as MRI or US [22–28]. The dur-
ation of pain was defined as more than 3 and 6 months
in one study [28] and in four studies [22, 25–27] re-
spectively, but there was no clear explanation in the
other two studies [23, 24]. The control tissues were ob-
tained from the same anatomical location except in one
study that investigated the gene expression in RC tear
compared with the hamstring tendons in patients going
under anterior cruciate ligament reconstruction surgery
[22]. In the other studies that utilized the same anatomy,
two studies obtained the control tissues from the un-
affected area diagnosed by US in the same tendon [25,
27], and one study used cadaveric samples [23]. One
study focused on a particular subtype of tendinopathy,
calcific tendinopathy [29]. The two studies that investi-
gated the gene expression of CTGF in RC tendon tear
tissues did not show significant differences compared
with the healthy tendon tissues [22, 27]. The studies in-
vestigating the effect of exercise in human tendons were
excluded because the primary objective was to investi-
gate the expression pattern across the spectrum of
tendon disease and not to assess the impact of activity in
tendons.
Expression of TGF-β, BMPs and CTGF in animal models of
tendon injury or overuse
There was a wide variety of animal injury models, and
the gene and protein expression of TGF-β was predom-
inantly increased in healing compared with healthy
Table 1 Main characteristics of studies and patients of the papers included for expression in the diseased human tendon tissues search
Author Year Journal Tendon Healthy control? Quantitative/semiquantitative
analysis and statistical tests
Investigated genes and proteins
TGF-β
Goodier et al. [22] 2016 Arthritis Res Ther Rotator
cuff
Yes Yes TGFβ1, TGFβR1, TGFβR2
Pingel et al. [25] 2013 Eur J Appl Physiol Achilles Yesa Yes TGFβ1
Pingel et al. [27] 2012 BMC Musculoskeletal
Disord
Achilles Yesa Yes TGFβ1
de Mos et al. [28] 2009 Am J Sports Med Achilles Yes Yes TGFβ
Fu et al. [24] 2002 Clin Orthop Relat Res Patella Yes Yes TGFβ1
Fenwick et al. [23] 2001 J Anat Achilles Yesb Yes TGFβ1, TGFβ2, TGFβ3, TGβR1,
TGβR2
BMPs
Goodier et al. [22] 2016 Arthritis Res Ther Rotator
cuff
Yes Yes BMP2, BMP7
Rui et al. [26] 2012 Knee Surg Sports Traumatol
Arthrosc
Patella Yes No BMP2, BMP4, BMP7
Oliva et al. [29] 2011 Eur Cell Mater Rotator
cuff
Yesa Yes BMP2, BMP4, BMP6
CTGF
Goodier et al. [22] 2016 Arthritis Res Ther Rotator
cuff
Yes Yes CTGF
Pingel et al. [27] 2012 BMC Musculoskeletal
Disord
Achilles Yesa Yes CTGF
aStudies that sampled control tissues from the macroscopically healthy region of the same tendon
bStudies that sampled control tissues from cadavers
BMP bone morphogenic protein, CTGF connective tissue growth factor, TGF-β transforming growth factor beta
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Table 2 Main characteristics of studies and animal models of the papers included for expression in the tendon injury or overuse
model tissues search









Zhang et al. [47] 2016 Matrix Biol Achilles, mouse Transection Yes Yes TGFβ1, TGFβ2, TGFβ3,
TGFβR1, TGFβR2
Gao et al. [30] 2013 PLoS One FD, rat Overuse Yes Yes TGFβ1
Heisterbach et al. [48] 2012 Knee Surg Sports
Traumatol Arthrosc
Achilles, rat Transection→ repair Yes Yes TGFβ1
Otoshi et al. [49] 2011 Arthroscopy Achilles, rat Removal Yes Yes TGFβ1
Lin et al. [50] 2010 Bone Achilles, rat Transection Yes Yes TGFβ1, TGFβ2, TGFβ3
Chen et al. [51] 2008 J Hand Surg Am FDP, chicken Transection→ repair Yes Yes TGFβ
Chan et al. [52] 2008 Wound Repair Regen Patella, rat Defect Yes Yes TGFβ1, TGFβ2, TGFβ3,
TGFβR1, TGFβR2
Würgler-Hauri et al. [53] 2007 J Shoulder Elbow Surg RC, rat Detach→ repair Yes No TGFβ1
Berglund et al. [54] 2006 J Hand Surg Am FDP, rabbit Division→ repair Yes Yes TGFβ1
Kobayashi et al. [55] 2006 J Shoulder Elbow Surg RC, rabbit Defect Yes No TGFβ
Galatz et al. [56] 2006 J Orthop Res RC, rat Transection→ repair Yes Yes TGFβ1, TGFβ3
Dahlgren et al. [57] 2005 J Orthop Res FDS, horse CI Yes No TGFβ1
Darmani et al. [58] 2004 Mediators Inflamm FD, rat Crush injury Yes No TGFβ
Ngo et al. [59] 2001 Plast Reconstr Surg FDP, rabbit Transection→ repair Yes No TGFβR1, TGFβR2,
TGFβR3
Chang et al. [60] 1997 Plast Reconstr Surg FDP, rabbit Transection→ repair Yes Yes TGFβ1
Natsu-ume et al. [61] 1997 J Orthop Res Patella, rat Transection Yes Yes TGFβ
BMPs
Zhang et al. [47] 2016 Matrix Biol Achilles, mouse Transection Yes Yes BMP1– BMP7, BMP12–
BMP14, BMPR1, BMPR2
Heisterbach et al. [48] 2012 Knee Surg Sports
Traumatol Arthrosc
Achilles, rat Transection→ repair Yes Yes BMP12
Yee Lui et al. [62] 2011 J Orthop Res Patella, rat CI Yes Yes BMP2, BMP4, BMP7
Lin et al. [50] 2010 Bone Achilles, rat Transection Yes Yes BMP2, BMP4, BMP7
Lui et al. [63] 2009 J Orthop Surg Res Patella, rat CI/defect Yes Yes BMP2
Eliasson et al. [64] 2008 Clin Orthop Relat Res Achilles, rat Transection Yes Yes BMP7, BMP12, BMP13,
BMP14, BMPR
Würgler-Hauri et al. [53] 2007 J Shoulder Elbow Surg RC, rat Detach→ repair Yes No BMP12, BMP13, BMP14
CTGF
Gao et al. [30] 2013 PLoS One FD, rat Overuse Yes Yes CTGF
Kietrys et al. [31] 2012 PLoS One FD, rat Overuse Yes Yes CTGF
Fedorczyk et al. [32] 2010 J Orthop Res FD, rat Overuse Yes Yes CTGF
Chen et al. [51] 2008 J Hand Surg Am FDP, chicken Transection Yes Yes CTGF
Asundi et al. [42] 2008 Eur J Appl Physiol FDP, rabbit Overuse Yes Yes CTGF
Würgler-Hauri et al. [53] 2007 J Shoulder Elbow Surg RC, rat Detach→ repair Yes No CTGF
Berglund et al. [54] 2006 J Hand Surg Am FDP, rabbit Division→ repair Yes Yes CTGF
Nakama et al. [43] 2006 J Orthop Res FDP, rabbit Overuse Yes Yes CTGF
BMP bone morphogenic protein, CI collagenase-induced, CTGF connective tissue growth factor, FD flexor digitorum, FDP flexor digitorum profundus, FDS flexor
digitorum superficialis, RC rotator cuff, TGF-β transforming growth factor beta
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tendon tissues. However, the temporal pattern of the
transition was inconsistent (Table 5). The expression of
BMPs and CTGF was variable and could be increased,
decreased or similar to that of the healthy tissues. In the
overuse models, the expression of TGF-β1 and CTGF
proteins did not show changes in the early stages of
intervention but increased after 3 months [30–32]
(Table 5). No animal studies of tendon overuse focused
on the expression of BMPs (Table 5).
Response of tendon cells to treatment by TGF-β, BMPs or
CTGF
There were no studies that investigated the differences
in the cellular response to treatment with TGF-β, BMPs
or CTGF by tendon cells from healthy and diseased hu-
man tendon tissues. Two studies used patella tendon
derived cells from rat models of acute-stage tendon heal-
ing: one showed that diseased tendon cells from a CI
tendon injury model had a higher cell signaling activity
of the canonical Smad pathway in response to BMP
stimulation compared with the healthy cells [33]; and
the other reported that the expression of ECM genes
such as collagens type I and III, decorin and biglycan to
TGF-β treatment goes through temporal changes during
tendon healing in a defect model [34] (Table 6).
Discussion
This study provides evidence for the involvement of
TGF-β, BMPs and CTGF in the pathogenesis and heal-
ing of tendon disease. Diseased tissues from tendinopa-
thy and tendon tear patients showed an inconsistent
expression of these fibrotic growth factors that could be
increased, decreased or similar to that of the healthy tis-
sues. We were not able to identify a consistent temporal
pattern in their expression along the development of the
disease. Differences in the cellular responses to TGF-β,
BMPs and CTGF in diseased compared with healthy
human tendon cells had not been considered. However,
animal studies of tendon injury healing showed a variety
of expression patterns of these growth factors over time,
and that the cellular activities of these factors also differ
according to the phase of the healing.
Because of the heterogeneity of the included studies,
we were not able to determine a specific role of TGF-β,
BMPs or CTGF in the development of tendon disease
but only suggest their involvement in the pathogenesis
of fibrotic repair. The general applicability of the results
is limited. Clinical samples were harvested from tendino-
pathy patients in all of the human studies, but the diag-
nosis criteria were nonuniform and the anatomical
location varied, which included the patella, Achilles and
RC. Gene expression and stimulatory effects of the pro-
fibrotic growth factors on cells have been shown to differ
by anatomical location in animal models [35, 36], and
this is likely also the case for humans although we did
not identify any studies assessing anatomical location in
humans. The selection of matched control tissues with
regards to clinical and ethical feasibility is another
Table 3 Main characteristics of studies and cells of the papers included for the cellular responses to treatment search
Author Year Journal Tendon Model Healthy control? Quantitative/semiquantitative
analysis and statistical tests
Treatment
TGF-β
Fu et al. [34] 2008 J Orthop Res Patella, rat Defect Yes Yes TGFβ1
BMPs
Lui and Wong [33] 2013 BMC Musculoskeletal Disord Patella, rat CI Yes Yes BMP2
BMP bone morphogenic protein, CI collagenase-induced, TGF-β transforming growth factor beta
Table 4 Expression of TGF-β, BMPs and CTGF in diseased
human tendon samples versus healthy control tendon




TGFβ Achilles ↑ [29]
TGFβ1 RC, Achilles, patella ↑ [25, 27] ↓ [22], ↑ [24], → [23]
TGFβ2 Achilles ↑ [23]
TGFβ3 Achilles → [23]
TGFβR1 RC, Achilles → [22, 23]
TGFβR2 RC, Achilles ↓ [22, 23]
BMP2 RC, patella → [29] ↑ [26]
BMP4 RC, patella ↓ [29] ↑ [26]
BMP6 RC ↓ [29]
BMP7 Patella ↑ [26]
CTGF Achilles → [27], ↓ [25]
Tear
TGFβ1 RC → [22] ↓ [22]
TGFβR1 RC ↓ [22] ↓ [22]
TGFβR2 RC ↑ [22] ↓ [22]
BMP2 RC → [22]
BMP7 RC → [22]
CTGF RC → [22]
BMP bone morphogenic protein, CTGF connective tissue growth factor, RC
rotator cuff, TGF-β transforming growth factor beta
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Table 5 Expression of TGF-β, BMPs and CTGF in animal models of tendon injury or overuse versus healthy control tendon
Animal Tendon and model Increased, unchanged, decreased in animal models vs control
Gene Protein
Injury models
TGFβ Rat Patella, transection (partial) ↑ (1, 3, 7, 14, 28, 56 d) [61]
Chicken FDP, transection→ repair ↑ (3 d), → (9, 14, 21 d) [51]
TGFβ1 Rat Achilles, transection → (2, 4, 6, 8 w) [48]
Achilles, removal → (2 d), ↑ (7 d), → (30, 90, 180 d) [49]
Mouse Achilles, transection ↑ (1, 2, 4 w) [47]
Rabbit FDP, division→ repair ↑ (3, 6, 12 d), → (24 d) [54]
FDP, transection→ repair → (1 d), ↑ (3, 7, 14, 28, 56 d) [60]
Horse FDS, CI ↑ (1, 2, 4 w), → (8 w), ↑ (24 w) [57] → (1, 2 w), ↑ (4, 8 w), → (24 w) [57]
TGFβ2 Rat Achilles, transection ↑ (3, 5, 10 w) [50] ↑ (3, 5, 10 w) [50]
Mouse Achilles, transection ↑ (1, 2, 4 w) [47]
TGFβ3 Rat Achilles, transection ↑ (3, 5, 10 w) [50] ↑ (3, 5, 10 w) [50]
Mouse Achilles, transection → (1 w), ↑ (2, 4 w) [47]
TGFβR1 Mouse Achilles, transection → (1 w), ↑ (2 w), → (4 w) [47]
TGFβR2 Mouse Achilles, transection ↑ (1, 2, 4 w) [47]
TGFβR3 Mouse Achilles, transection → (1, 2, 4 w) [47]
BMP1 Mouse Achilles, transection ↑ (1, 2, 4 w) [47]
BMP2 Rat Achilles, transection ↑ (3, 5, 10 w) [50] ↑ (3, 5, 10 w) [50]
Patella, CI ↑ (2 w), → (4, 12 w) [63] ↑ (2, 4, 8, 12 w) [62, 63], ↑ (16 w) [62]
Patella, defect → (2, 4, 12 w) [63] ↑ (2, 4, 12 w) [63]
Mouse Achilles, transection ↓ (1, 2, 4 w) [47]
BMP3 Mouse Achilles, transection ↑ (1, 2, 4 w) [47]
BMP4 Rat Achilles, transection ↑ (3, 5, 10 w) [50] ↑ (3, 5 w), → (10 w) [50]
Patella, CI ↑ (2, 4, 8, 12, 16 w) [62]
Mouse Achilles, transection → (1 w), ↑ (2, 4 w) [47]
BMP5 Mouse Achilles, transection → (1 w), ↑ (2, 4 w) [47]
BMP6 Mouse Achilles, transection → (1, 2, 4 w) [47]
BMP7 OP-1 Rat Achilles, transection ↑ (3, 5, 10 w) [50] ↑ (3, 5, 10 w) [50]
Achilles, transection→ unload ↑ (3, 8 d), → (14, 21 d) [64]
Achilles, transection→ load → (3, 8, 14 d), ↓ (14, 21 d) [64]
Patella, CI ↑ (2, 4, 8, 12, 16 w) [62]
Mouse Achilles, transection → (1 w), ↑ (2, 4 w) [47]
BMP12 Rat Achilles, transection ↑ (2 w), → (4, 6, 8 w) [48]
Achilles, transection→ unload ↓ (3, 8 d), → (14, 21 d) [64]
Achilles, transection→ load ↓ (3, 8 d), → (14, 21 d) [64]
Mouse Achilles, transection → (1 w), ↑ (2, 4 w) [47]
BMP13 Rat Achilles, transection→ unload → (3, 8, 14 d), ↓ (21 d) [64]
Achilles, transection→ load → (3, 8, 14 d), ↓ (21 d) [64]
Mouse Achilles, transection → (1, 2, 4 w) [47]
BMP14 Rat Achilles, transection→ unload ↓ (3, 8, 14, 21 d) [64]
Achilles, transection→ load ↓ (3, 8, 14, 21 d) [64]
Mouse Achilles, transection ↓ (1 w), ↑ (2 w), → (4 w) [47]
BMPR1a Mouse Achilles, transection ↑ (1, 2, 4 w) [47]
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concern. In one study the control tissues were obtained
from the hamstring tendons in patients going under an-
terior cruciate ligament reconstruction surgery in com-
parison with RC tear tendons [22], with an age
difference between the two cohorts that could be a po-
tential confounder in humans [37–39], unlike animals
[40]. Whether an ultrasonographically intact region of a
diseased tendon represents a healthy tissue remains con-
troversial, and cadaveric tissue samples have their limita-
tions in the traceability of tendon disease history and the
effects of postmortem change [22].
For the studies of animal tendon injury models, only
the studies that measured the temporal changes were in-
cluded so that the results came in line with the primary
objective of assessing differences between the stages of a
tendon disease. Only the studies that used quantitative
measures and statistical methods for comparison for
their results were included (Table 5), but there was also
a variation in the methods of analysis. Various animal
models of tendinopathy have been proposed, but
because they do not always account for the effects of
aging and development of fibrosis, whether they accur-
ately recapitulate human disease is open to debate [41].
We included the studies of overuse models that
confirmed the development of tendinopathy after the
intervention with (semi)quantitative methods such as
changes in cellularity [30, 31], infiltration of inflamma-
tory cells [32] and disorganized collagen fibers by hist-
ology [42, 43]. The expression of TGF-β1 and CTGF
proteins increased after 3 months of overloading tasks
corresponding to tendinopathy development, but not in
the early stages of intervention [30–32].
We have indicated that the gene and protein expression
of TGF-β and BMPs varies across the stage of tendon dis-
ease, and that cellular activities go through changes
accordingly. This is in line with a previous study reporting
the differences in the cellular response to TGF-β in hu-
man fibroblasts derived from normal skin and the skin of
a hypertrophic scar [44]. Involvement of CTGF could not
be established in human disease because only two studies
looked at this growth factor [22, 25], and no difference in
gene expression between healthy and diseased tendon was
detected. There were also no studies that investigated dif-
ferences in cellular activities in response to CTGF
between cells from different stages of a tendon disease or
injury healing. Further investigation is necessary to
enhance our understanding of the role of TGF-β, BMPs
and CTGF in tendon disease.
This review also highlights the paucity of analyses of
human-derived tendon tissue and cells. The majority of
studies to date have attempted to modify disease pro-
gression or improve healing by adjusting the expression
of the fibrotic mediators that was found to be
Table 5 Expression of TGF-β, BMPs and CTGF in animal models of tendon injury or overuse versus healthy control tendon
(Continued)
BMPR1b Rat Achilles, transection→ unload ↓ (3 d), → (8 d), ↑ (14 d), ↓ (21 d) [64]
Achilles, transection→ load → (3, 8, 14 d), ↓ (21 d) [64]
Mouse Achilles, transection → (1 w), ↑ (2, 4 w) [47]
BMPR2 Rat Achilles, transection→ unload → (3 d), ↑ (8, 14 d), ↓ (21 d) [64]
Achilles, transection→ load → (3 d), ↑ (8, 14 d), ↓ (21 d) [64]
Mouse Achilles, transection ↑ (1, 2, 4 w) [47]
CTGF Rabbit FDP, division→ repair → (3, 6, 12, 24 d) [54]
Chicken FDP, transection→ repair ↑ (3 d), → (9 d), ↓ (14, 21 d) [51]
Overuse models
TGFβ1 Rat FD, hand-pulling task → (18 w), ↑ (24 w) [30]
CTGF Rat RC, hand-pulling task ↑ (12 w) [31]
FD, hand-pulling task ↑ (18, 24 w) [30]
→ (3, 6 w), ↑ (12 w) [32]
Rabbit FDP, electrical stimulation →[42] ↑[43]
BMP bone morphogenic protein, CI collagenase-induced, CTGF connective tissue growth factor, d day(s), FD flexor digitorum, FDP flexor digitorum profundus, FDS
flexor digitorum superficialis, RC rotator cuff, TGF-β transforming growth factor beta, w week(s)
Table 6 Cellular responses to treatment by TGF-β and BMPs in
injured versus healthy tendon cells
Increased, unchanged, decreased in diseased
vs control




Bgn→ (day 7 healing) [34]
Col1a1→, Col3a1→, Dcn↑,
Bgn↓ (day 14 healing) [34]
BMP2 Patella, rat, CI p-Smad1/5/
8↑ [33]
BMP bone morphogenic protein, CI collagenase-induced, TGF-β transforming
growth factor beta
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remarkable in diseased tendons, without a comprehen-
sive understanding of their role and mechanisms in the
development of the disease. Cells from clinical samples
of tendinopathy show an altered phenotype [45] and the
cellular activities of RC tear tendon cells may likewise
differ according to the severity of the disease [46]. Des-
pite these differential cellular responses, the majority of
in vitro tendinopathy studies have not taken this into ac-
count. It is imperative to recognize that cultured tendon
cells from intact as opposed to diseased tendons may
not recapitulate the actual healing or disease develop-
ment process with regards to cell proliferation and syn-
thesis of ECM proteins [45]. Animal models have been
beneficial in increasing the understanding of tendon dis-
ease progression and healing, but do not replicate the
continuum of tendon disease [22]. It should be noted
that cautious interpretation of animal studies is neces-
sary. The most effective method to investigate the mech-
anism of human tendon pathophysiology is to use fresh
well-phenotyped tissue from human patients with ac-
ceptable control samples. Understanding the interaction
of cells and fibrotic mediators that drive fibrosis in the
pathophysiology of tendon disease would be essential in
order to identify the fundamental interventions, and
therefore it is critical to appropriately define the details
of the specimen such as origin of the tissues or cell,
phase of the disease, criteria and method of diagnosis. In
tendon disease, the importance of considering the ap-
propriate disease phase and the corresponding interven-
tion has been recognized [19]; however, the sequential
regulation and interaction of the TGF-β, BMPs and
CTGF with tendon cells is not yet well understood. Fu-
ture work should investigate the temporal expression of
these fibrotic growth factors and their interaction with
tendon cells using well-phenotyped patient samples at
different stages of tendon disease. This research will ad-
vance our knowledge of the pathophysiology of tendon
disease, and will facilitate identification of potential
therapeutic targets to enhance the quality of tissue repair
or influence disease progression.
Conclusions
The expression of the TGF-β, BMPs and CTGF is dys-
regulated in diseased human tendon tissues, but the
transition during the development of the disease is yet
to be defined. Cell behavior in response to these growth
factors in human tendon cells along the course of path-
ology has not been explored. Importantly this review
highlights the paucity of analyses of human-derived ten-
don tissues and cells. Further research using well-
phenotyped patient samples at different stages of tendon
disease is warranted to improve the understanding of
disease pathogenesis.
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